8-K: Onconetix Announces New Clinical Data for Prostate Cancer Test Proclarix at European Urology Congress

Onconetix's Proclarix prostate cancer test data will be presented at the 2025 European Association of Urology Congress.

Summary

• Onconetix, Inc. announced that an abstract featuring new clinical data for its Proclarix prostate cancer test has been accepted for presentation at the 2025 European Association of Urology (EAU) Congress in Madrid, Spain.
• The presentation, titled 'Clinical Performance of Proclarix in Ruling Out Clinically Insignificant or No Prostate Cancer: Evaluation in a Danish Cohort,' will highlight Proclarix performance results from a study of over 800 patients from Lillebaelt Hospital University Hospital of Southern Denmark.
• Proclarix is a CE-certified in vitro diagnostic test indicated for prostate cancer diagnosis in patients with normal digital rectal exam (DRE), enlarged prostate volume and elevated PSA levels at 2-10 ng/ml.
• The test combines in-vitro assays for the quantitative detection of biomarkers with a proprietary algorithm to assess a patient's risk of having clinically significant prostate cancer.
• Onconetix anticipates marketing Proclarix in the U.S. as a lab developed test (LDT) through its license agreement with Labcorp.

Sentiment

Score: 7

Explanation: The announcement is positive, highlighting the presentation of clinical data for Proclarix at a major urology congress. While forward-looking statements include standard risk disclosures, the overall tone is optimistic about the potential of Proclarix.

Positives

• Proclarix has demonstrated the ability to reduce unnecessary biopsies by ruling out patients with clinically insignificant or no prostate cancer.
• Proclarix is included in both the European (EAU) and American (AUA) guidelines.
• The company owns ENTADFI, an FDA-approved treatment for benign prostatic hyperplasia (BPH).

Risks

• The company's ability to commercialize or monetize Proclarix is subject to market conditions and other risks.
• The company needs capital to commercially launch Proclarix and maintain adequate working capital.
• The company's ability to attract, hire, and retain skilled personnel is a risk factor.
• Failure to obtain and maintain necessary regulatory approvals is a risk.
• The company's ability to maintain compliance with Nasdaq's listing criteria is a risk.

Future Outlook

The company anticipates marketing Proclarix in the U.S. as a lab developed test (LDT) through its license agreement with Labcorp.

Management Comments

• Ralph Schiess, PhD, CEO of Proteomedix, stated that Proclarix has demonstrated in multiple studies that it can be safely used to reduce performed biopsies by ruling out patients with clinically insignificant or no prostate cancer while minimizing the risk of missing clinically significant cancer when compared to standard of care.

Industry Context

The announcement highlights Onconetix's efforts to establish Proclarix as a key diagnostic tool in the prostate cancer market, aligning with the industry's focus on early and accurate detection to improve patient outcomes. The inclusion of Proclarix in both European (EAU) and American (AUA) guidelines underscores its growing acceptance within the medical community.

Comparison to Industry Standards

• Proclarix is positioned as a competitor to existing prostate cancer diagnostic tests, such as the Prostate Health Index (PHI) and 4Kscore test, which also aim to improve risk stratification and reduce unnecessary biopsies.
• The study involving over 800 patients is a significant sample size for evaluating the clinical performance of a diagnostic test, comparable to studies conducted for other established prostate cancer biomarkers.
• The CE certification under In Vitro Diagnostic Regulation (IVDR) demonstrates compliance with European regulatory standards, similar to other IVD products marketed in the EU.

Stakeholder Impact

• Shareholders may react positively to the news of Proclarix data being presented at a major medical congress.
• Healthcare professionals will gain access to new data on Proclarix's performance in prostate cancer diagnosis.
• Patients may benefit from improved prostate cancer risk assessment and reduced unnecessary biopsies.

Next Steps

• Presentation of Proclarix data at the 2025 European Association of Urology Congress.
• Continued efforts to commercialize Proclarix in the U.S. as a lab developed test (LDT) through the agreement with Labcorp.

Key Dates